Chronic treatment with Tadalafil improves endothelial function in men with increased cardiovascular risk

Giuseppe M C Rosano, Antonio Aversa, Cristiana Vitale, Andrea Fabbri, Massimo Fini, Giovanni Spera

Research output: Contribution to journalArticle

202 Citations (Scopus)

Abstract

Erectile dysfunction (ED) is often associated with a cluster of risk factors for coronary artery disease and reduced endothelial function. Acute and chronic administration of oral sildenafil, a phosphodiesterase type 5 (PDE5) inhibitor, improves endothelial function in patients with ED. Tadalafil (TAD) is a new PDE5 inhibitor with a long half life that allows alternate day administration. Aim of the study was to evaluate whether chronic therapy (4 weeks) with TAD improves endothelial function in patients with increased cardiovascular risk and whether this effect is sustained after discontinuation of therapy. We randomized 32 patients with increased cardiovascular risk to receive either TAD 20 mg on alternate days or matching placebo (PLB) for 4 weeks. Patients underwent evaluation of brachial artery flow-mediated dilation (FMD), nitrite/nitrate and endothelin-1 plasma levels at baseline, at the end of treatment period and after two-weeks follow-up. At 4 weeks, FMD was significantly improved by TAD (from 4.2 ± 3.2 to 9.3 ± 3.7%, p <0.01 vs. baseline), but was not modified by PLB (from 4.1 ± 2.8 to 4.0 ± 3.4%, p = NS). At 6 weeks the benefit in FMD was sustained in patients that received TAD (9.1 ± 3.9% vs. 4.2 ± 3.2%, p = 0.01 vs. baseline; 9.1 ± 3.9% vs. 9.3 ± 3.7%, vs. 4 weeks, p = NS) while no changes in FMD were observed in patients randomized to PLB. Also, compared to baseline, a net increase in nitrite/nitrate levels (38.2 ± 12.3 vs. 52.6 ± 11.7 and 51.1 ± 3.1, p <0.05) and a decrease in endothelin-1 levels (3.3 ± 0.9 vs. 2.9. ± 0.7 and 2.9 ± 0.9, p <0.05) was found both at four and six-weeks after TAD; these changes were inversely correlated as shown by regression analysis (adjusted R 2 = 0.81, p <0.0001). Chronic therapy with TAD improves endothelial function in patients with increased cardiovascular risk regardless their degree of ED. The benefit of this therapy is sustained for at least two weeks after the discontinuation of therapy. Larger studies are needed in order to assess the possible clinical implications of chronic therapy with TAD.

Original languageEnglish
Pages (from-to)214-222
Number of pages9
JournalEuropean Urology
Volume47
Issue number2
DOIs
Publication statusPublished - Feb 2005

Fingerprint

Dilatation
Erectile Dysfunction
Phosphodiesterase 5 Inhibitors
Placebos
Endothelin-1
Therapeutics
Nitrites
Nitrates
Brachial Artery
Tadalafil
Oral Administration
Half-Life
Coronary Artery Disease
Regression Analysis

Keywords

  • Arterial dilatation
  • Endothelial dysfunction
  • Erectile dysfunction
  • Phosphodiesterase type 5
  • Rehabilitation

ASJC Scopus subject areas

  • Urology

Cite this

Chronic treatment with Tadalafil improves endothelial function in men with increased cardiovascular risk. / Rosano, Giuseppe M C; Aversa, Antonio; Vitale, Cristiana; Fabbri, Andrea; Fini, Massimo; Spera, Giovanni.

In: European Urology, Vol. 47, No. 2, 02.2005, p. 214-222.

Research output: Contribution to journalArticle

@article{3435de9c795c47cb8997ec18925c2f11,
title = "Chronic treatment with Tadalafil improves endothelial function in men with increased cardiovascular risk",
abstract = "Erectile dysfunction (ED) is often associated with a cluster of risk factors for coronary artery disease and reduced endothelial function. Acute and chronic administration of oral sildenafil, a phosphodiesterase type 5 (PDE5) inhibitor, improves endothelial function in patients with ED. Tadalafil (TAD) is a new PDE5 inhibitor with a long half life that allows alternate day administration. Aim of the study was to evaluate whether chronic therapy (4 weeks) with TAD improves endothelial function in patients with increased cardiovascular risk and whether this effect is sustained after discontinuation of therapy. We randomized 32 patients with increased cardiovascular risk to receive either TAD 20 mg on alternate days or matching placebo (PLB) for 4 weeks. Patients underwent evaluation of brachial artery flow-mediated dilation (FMD), nitrite/nitrate and endothelin-1 plasma levels at baseline, at the end of treatment period and after two-weeks follow-up. At 4 weeks, FMD was significantly improved by TAD (from 4.2 ± 3.2 to 9.3 ± 3.7{\%}, p <0.01 vs. baseline), but was not modified by PLB (from 4.1 ± 2.8 to 4.0 ± 3.4{\%}, p = NS). At 6 weeks the benefit in FMD was sustained in patients that received TAD (9.1 ± 3.9{\%} vs. 4.2 ± 3.2{\%}, p = 0.01 vs. baseline; 9.1 ± 3.9{\%} vs. 9.3 ± 3.7{\%}, vs. 4 weeks, p = NS) while no changes in FMD were observed in patients randomized to PLB. Also, compared to baseline, a net increase in nitrite/nitrate levels (38.2 ± 12.3 vs. 52.6 ± 11.7 and 51.1 ± 3.1, p <0.05) and a decrease in endothelin-1 levels (3.3 ± 0.9 vs. 2.9. ± 0.7 and 2.9 ± 0.9, p <0.05) was found both at four and six-weeks after TAD; these changes were inversely correlated as shown by regression analysis (adjusted R 2 = 0.81, p <0.0001). Chronic therapy with TAD improves endothelial function in patients with increased cardiovascular risk regardless their degree of ED. The benefit of this therapy is sustained for at least two weeks after the discontinuation of therapy. Larger studies are needed in order to assess the possible clinical implications of chronic therapy with TAD.",
keywords = "Arterial dilatation, Endothelial dysfunction, Erectile dysfunction, Phosphodiesterase type 5, Rehabilitation",
author = "Rosano, {Giuseppe M C} and Antonio Aversa and Cristiana Vitale and Andrea Fabbri and Massimo Fini and Giovanni Spera",
year = "2005",
month = "2",
doi = "10.1016/j.eururo.2004.10.002",
language = "English",
volume = "47",
pages = "214--222",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier B.V.",
number = "2",

}

TY - JOUR

T1 - Chronic treatment with Tadalafil improves endothelial function in men with increased cardiovascular risk

AU - Rosano, Giuseppe M C

AU - Aversa, Antonio

AU - Vitale, Cristiana

AU - Fabbri, Andrea

AU - Fini, Massimo

AU - Spera, Giovanni

PY - 2005/2

Y1 - 2005/2

N2 - Erectile dysfunction (ED) is often associated with a cluster of risk factors for coronary artery disease and reduced endothelial function. Acute and chronic administration of oral sildenafil, a phosphodiesterase type 5 (PDE5) inhibitor, improves endothelial function in patients with ED. Tadalafil (TAD) is a new PDE5 inhibitor with a long half life that allows alternate day administration. Aim of the study was to evaluate whether chronic therapy (4 weeks) with TAD improves endothelial function in patients with increased cardiovascular risk and whether this effect is sustained after discontinuation of therapy. We randomized 32 patients with increased cardiovascular risk to receive either TAD 20 mg on alternate days or matching placebo (PLB) for 4 weeks. Patients underwent evaluation of brachial artery flow-mediated dilation (FMD), nitrite/nitrate and endothelin-1 plasma levels at baseline, at the end of treatment period and after two-weeks follow-up. At 4 weeks, FMD was significantly improved by TAD (from 4.2 ± 3.2 to 9.3 ± 3.7%, p <0.01 vs. baseline), but was not modified by PLB (from 4.1 ± 2.8 to 4.0 ± 3.4%, p = NS). At 6 weeks the benefit in FMD was sustained in patients that received TAD (9.1 ± 3.9% vs. 4.2 ± 3.2%, p = 0.01 vs. baseline; 9.1 ± 3.9% vs. 9.3 ± 3.7%, vs. 4 weeks, p = NS) while no changes in FMD were observed in patients randomized to PLB. Also, compared to baseline, a net increase in nitrite/nitrate levels (38.2 ± 12.3 vs. 52.6 ± 11.7 and 51.1 ± 3.1, p <0.05) and a decrease in endothelin-1 levels (3.3 ± 0.9 vs. 2.9. ± 0.7 and 2.9 ± 0.9, p <0.05) was found both at four and six-weeks after TAD; these changes were inversely correlated as shown by regression analysis (adjusted R 2 = 0.81, p <0.0001). Chronic therapy with TAD improves endothelial function in patients with increased cardiovascular risk regardless their degree of ED. The benefit of this therapy is sustained for at least two weeks after the discontinuation of therapy. Larger studies are needed in order to assess the possible clinical implications of chronic therapy with TAD.

AB - Erectile dysfunction (ED) is often associated with a cluster of risk factors for coronary artery disease and reduced endothelial function. Acute and chronic administration of oral sildenafil, a phosphodiesterase type 5 (PDE5) inhibitor, improves endothelial function in patients with ED. Tadalafil (TAD) is a new PDE5 inhibitor with a long half life that allows alternate day administration. Aim of the study was to evaluate whether chronic therapy (4 weeks) with TAD improves endothelial function in patients with increased cardiovascular risk and whether this effect is sustained after discontinuation of therapy. We randomized 32 patients with increased cardiovascular risk to receive either TAD 20 mg on alternate days or matching placebo (PLB) for 4 weeks. Patients underwent evaluation of brachial artery flow-mediated dilation (FMD), nitrite/nitrate and endothelin-1 plasma levels at baseline, at the end of treatment period and after two-weeks follow-up. At 4 weeks, FMD was significantly improved by TAD (from 4.2 ± 3.2 to 9.3 ± 3.7%, p <0.01 vs. baseline), but was not modified by PLB (from 4.1 ± 2.8 to 4.0 ± 3.4%, p = NS). At 6 weeks the benefit in FMD was sustained in patients that received TAD (9.1 ± 3.9% vs. 4.2 ± 3.2%, p = 0.01 vs. baseline; 9.1 ± 3.9% vs. 9.3 ± 3.7%, vs. 4 weeks, p = NS) while no changes in FMD were observed in patients randomized to PLB. Also, compared to baseline, a net increase in nitrite/nitrate levels (38.2 ± 12.3 vs. 52.6 ± 11.7 and 51.1 ± 3.1, p <0.05) and a decrease in endothelin-1 levels (3.3 ± 0.9 vs. 2.9. ± 0.7 and 2.9 ± 0.9, p <0.05) was found both at four and six-weeks after TAD; these changes were inversely correlated as shown by regression analysis (adjusted R 2 = 0.81, p <0.0001). Chronic therapy with TAD improves endothelial function in patients with increased cardiovascular risk regardless their degree of ED. The benefit of this therapy is sustained for at least two weeks after the discontinuation of therapy. Larger studies are needed in order to assess the possible clinical implications of chronic therapy with TAD.

KW - Arterial dilatation

KW - Endothelial dysfunction

KW - Erectile dysfunction

KW - Phosphodiesterase type 5

KW - Rehabilitation

UR - http://www.scopus.com/inward/record.url?scp=12344288164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12344288164&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2004.10.002

DO - 10.1016/j.eururo.2004.10.002

M3 - Article

C2 - 15661417

AN - SCOPUS:12344288164

VL - 47

SP - 214

EP - 222

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 2

ER -